Tempus Agrees to Acquire Cancer Test Maker Personalis for $1.5 Billion
Tempus AI announced it will acquire cancer diagnostics company Personalis for $1.5 billion, aiming to enhance its capabilities in supporting patients through cancer diagnostics and monitoring. The deal includes a per-share price of $16.25, offering a 6% premium over the closing price on Friday.
Tickers: $ABT $EXAS $PSNL $TEM
Topics: biotech cancer diagnostics healthcare medtech